Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009828 | 1.00 | SLC22A6 (0.46) | SLC22A6GABRR1LMNASMN1; SMN2CA2 | |
| SCHEMBL8769052 | 0.90 | SLC22A6 (0.52) | SLC22A6GABRR1LMNASMN1; SMN2CA2 | |
| SCHEMBL2130208 | 0.90 | SLC22A6 (0.52) | SLC22A6GABRR1LMNASMN1; SMN2CA2 | |
| SCHEMBL2907101 | 0.90 | SLC22A6 (0.52) | SLC22A6GABRR1LMNASMN1; SMN2CA2 | |
| SCHEMBL5712806 | 0.85 | TGFBR1 (0.42) | SLC22A6LMNACA2MMEOR51E2 | |
| SCHEMBL5712807 | 0.85 | TGFBR1 (0.42) | SLC22A6LMNACA2MMEOR51E2 | |
| SCHEMBL8422815 | 0.85 | SLC22A6 (0.43) | SLC22A6GABRR1LMNASMN1; SMN2MAPT | |
| SCHEMBL7860337 | 0.82 | GABRR1 (0.59) | SLC22A6GABRR1LMNASMN1; SMN2CA2 | |
| SCHEMBL6234376 | 0.81 | SMN1; SMN2 (0.42) | SLC22A6GABRR1LMNASMN1; SMN2CA2 | |
| SCHEMBL6234365 | 0.81 | SMN1; SMN2 (0.42) | SLC22A6GABRR1LMNASMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | SLC22A6 2299/4885GABRR1 2260/4885LMNA 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.